Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis

Siddiqui, Mohammad Shadab; Carbone, Salvatore; Vincent, Robert; Patel, Samarth; Driscoll, Carolyn; Celi, Francesco S.; Billingsley, Hayley; Rotelli, Brando; John, Binu; Potere, Nicola; Viscusi, Michele Mattia; Adiletta, Veronica; Sanyal, Arun J.; Luketic, Velimir A.; Reichman, Trevor; Bhati, Chandra

doi:10.1016/j.cgh.2018.11.008

Cited by 13 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of parents having LSM >7.9 kPa was 41 (40.19%) vs only 17 (17%) among parents of both groups (P = 0.025). Similar to a study carried out, Siddiqui et al 18,24 studied caregivers of patients with NAFLD-related cirrhosis and found the median LSM value of 6.7 kPa (4.4-9.7) with the distribution of fibrosis stage 2, 3, and 4 as 28%, 28%, and 14%, respectively. Liver cirrhosis was found in 5 (4.9%) parents of the NAFLD group, while none of the parents from the non-NAFLD group had cirrhosis.…”

Section: Discussionsupporting

confidence: 66%

“…Similarly, one prospective study which used MR spectroscopy among siblings and parents of probands with fatty liver detected fatty liver in 59% and 78%, respectively, compared with 17% and 37% among relatives of probands without fatty liver. 16 Siddiqui et al 18 found that the prevalence of the disease in relatives is nearly 3 times higher than that of the general population if the patient had early decompensated NAFLD-related cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?

Jain

Thanage

Panchal

et al. 2021

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?

Jain

Thanage

Panchal

et al. 2021

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…Despite these recommendations, acceptance of dietary interventions is challenging because of the close association between dietary habits, culture and ethnicity. In addition, many patients with NASH cirrhosis have a caregiver with NASH, probably because of shared lifestyle‐related risk factors . Ideally, dietary interventions should be applied to the entire household.…”

Section: Weight Loss With Lifestyle Measuresmentioning

confidence: 99%

“…In addition, many patients with NASH cirrhosis have a caregiver with NASH, probably because of shared lifestyle-related risk factors. 4 Ideally, dietary interventions should be applied to the entire household. This can help with adherence to the diet as well as potentially benefit caregivers at risk of the metabolic syndrome and its associations.…”

Section: Introductionmentioning

confidence: 99%

Current management of non‐alcoholic steatohepatitis

Muthiah

Sanyal

2020

Liver International

Self Cite

View full text Add to dashboard Cite

Non‐alcoholic steatohepatitis (NASH) is the most common cause of liver disease in Western populations, and its prevalence is increasing rapidly. It is part of a multisystem disease affecting other organs such as the kidneys, heart and blood vessels, and is closely associated with the components of the metabolic syndrome. Physicians managing patients with NASH should not only focus on the management of NASH, but also on associated comorbidities in individual patients. The approaches to treatment of NASH include either limiting energy surplus alone, or in combination with targeting of downstream pathways of inflammation and fibrosis. In this mini‐review, we discuss the currently available treatment options for NASH, as well as those in late‐stage clinical trials. We discuss the challenges of managing these patients with a limited number of approved therapies, as well as managing advanced‐stage patients with NASH and cirrhosis. We also discuss the specific management of comorbidities in NASH patients, in particular diabetes, hypertension, dyslipidaemia and cardiovascular diseases. Finally, we present the screening protocols for both hepatocellular carcinoma and extrahepatic malignancies in these patients.

show abstract

“…Another key factor limiting the success of medical weight loss approaches is the expectation that the patient will change their food habits, while the rest of the family does not. We have recently found that in those with NASH cirrhosis, a large number of caregivers also have the condition and this is almost certainly linked to common lifestyle‐related risk factors . It is therefore important to engage the entire family unit in changing lifestyle.…”

Section: Practical Considerations In the Use Of Drug Therapy For Nashmentioning

confidence: 99%

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis

Noureddin

Muthiah

Sanyal

2019

Endocrino Diabet & Metabol

Self Cite

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) affects almost a third of the Western population, and the burden of the disease is set to rise exponentially. 1 Current drug therapies for the resulting nonalcoholic steatohepatitis (NASH) are limited in their efficacy, and there are no FDA-approved drugs for NASH. 2 In this article, we review the potential therapeutic targets for NASH and their biological rationale, the current state of drugs in clinical trials, as well as some practical considerations as to how we manage NASH in the clinic. 2 | TRE ATMENT TARG E TS FOR THER APEUTI C S IN NA S H 2.1 | Targeting homeostasis of lipid and carbohydrate metabolism Excess delivery of fatty acids to the liver or impaired disposal of fatty acids from the liver leads to excess energy supply. Hepatocytes are unable to process this excess energy, forming lipotoxic metabolites with hepatocellular injury. 3 Systemic insulin resistance contributes to this, via increased adipose lipolysis leading to increased delivery

show abstract

Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis

Cited by 13 publications

References 8 publications

Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?

Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?

Current management of non‐alcoholic steatohepatitis

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis

Contact Info

Product

Resources

About